Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.45 |
| ▸ | F9 | P00740 | 1/20 | 0.45 |
| ▸ | GCK | P35557 | 1/20 | 0.45 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663864 | 1.00 | NR4A2 (0.59) | NR4A2NPC1RAB9AMAOBMAOA | |
| SCHEMBL9946041 | 0.88 | NR4A2 (0.57) | NR4A2NPC1RAB9AMAOBMAOA | |
| SCHEMBL2562469 | 0.85 | NR4A2 (0.61) | NR4A2NPC1RAB9AENPP2NR4A1 | |
| SCHEMBL2562164 | 0.84 | ENPP2 (0.50) | NR4A2NPC1RAB9AENPP2MEN1 | |
| SCHEMBL2558815 | 0.83 | NR4A2 (0.46) | NR4A2NPC1RAB9AMAOBMAOA | |
| SCHEMBL2556153 | 0.83 | NR4A2 (0.60) | NR4A2NPC1RAB9AMAOBMAOA | |
| SCHEMBL29954245 | 0.83 | NR4A2 (0.60) | NR4A2NPC1RAB9AMAOBMAOA | |
| SCHEMBL15332443 | 0.82 | CCNB2 (0.52) | NR4A2NPC1RAB9AMAOBENPP2 | |
| SCHEMBL4317982 | 0.82 | MAOB (0.51) | MAOBENPP2SPHK2SPHK1F9 | |
| SCHEMBL31240558 | 0.82 | MAOB (0.51) | MAOBENPP2SPHK2SPHK1F9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361484-B2 | Polymer systems for lung volume reduction therapy | AERIS THERAPEUTICS, INC. (US) | 2013-01-29 | — | — | US | claimed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | claimed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | claimed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-04-04 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20210078978-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-18 | — | — | US | disclosed |
| US-10851083-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-01 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20180215732-A9 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-02 | — | — | US | disclosed |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | CANADIAN IMPERIAL BANK OF COMMERCE (CA) | 2010-02-18 | — | — | US | disclosed |
| WO-2009134754-A1 | BENZOIMIDAZOLE GLYCINAMIDES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134750-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-11-05 | — | — | WO | disclosed |
| EP-2059227-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | Aeris Therapeutics, Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY DISCOVERY, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008039827-A2 | POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY | AERIS THERAPEUTICS, INC. (US) | 2008-04-03 | — | — | WO | disclosed |
| WO-2005014525-A2 | BI-ARYL COMPOUND HAVING IMMUNOSUPPRESSIVE ACTIVITY | MITSUBISHI PHARMA CORPORATION (JP) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11618744-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | P4HA1, PAH, EGLN3 | NR4A2 2078/4885NPC1 1042/4885RAB9A 3990/4885 |
| US-20090099131-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | NR4A2 3742/4885NPC1 570/4885RAB9A 1975/4885 |
| US-10851083-B2 | Benzoimidazoles as prolyl hydroxylase inhibitors | P4HA1, PAH, EGLN3 | NR4A2 2078/4885NPC1 1042/4885RAB9A 3990/4885 |
| US-20180215732-A9 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | NR4A2 2078/4885NPC1 1042/4885RAB9A 3990/4885 |
| US-20100040538-A1 | Polymer Systems for Lung Volume Reduction Therapy | GFER, MUC1, CTH | NR4A2 3925/4885NPC1 4840/4885RAB9A 4705/4885 |
| US-20210078978-A1 | BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, PAH, EGLN3 | NR4A2 2078/4885NPC1 1042/4885RAB9A 3990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.